Skip to main content

COVID-19 Lung Transplant International Registry

Lung transplantation has been the sole option for such patients with end-stage lung disease for COVID-19. With the advent of the first lung transplant for patients with non-resolving COVID-19-associated respiratory failure, there has been global interest in performing lung transplant for this unique population of COVID-19 patients. While the numbers of cases of lung transplant for COVID-19-associated respiratory failure have increased significantly, there is a paucity of data on these patients.

The data collected through this registry will benefit society and future patients by being used to inform subsets of patients who may benefit from transplant.


What is this registry?

  • This registry is for patients who have undergone lung transplant for COVID-19-associated respiratory failure. This registry will capture information on pre-transplant status, surgical requirements and post-transplant outcomes.
  • The registry will be open to any site, anywhere in the world, that wants to submit data and will be collected in an such a way to limit collection of protected health information to facilitate easy of participation.

Who is included in this study?

  • Individuals of any age who undergo single or bilateral lung transplant for COVID-19-associated respiratory failure.
  • Listing for your transplant has to occur after diagnosis of COVID-19 and complications of COVID-19 have to be the primary reason for transplant

*This study does not include individuals who were considered for transplant and subsequently became infected with COVID-19 or patients who were listed for or were being evaluated for lung transplant before COVID-19 diagnosis.

What about my information?

  • No patient identifiers will be collected in the application and only summary data will be presented publicly
  • The registry will be housed at Northwestern University Feinberg School of Medicine and is IRB approved by the NU IRB. 
  • Sites will not be submitting identifiable personal health information (PHI) and therefore should not need local IRB approval or a DUA. 
  • If you feel that you need IRB approval or DUA, please reach out to Michael Ison ( 


 If you have questions, please reach out to Michael Ison ( 


Submit your case using this link


Key Documents:

Follow NUTORC on LinkedIn